Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could charcoal and probiotics protect kidneys in diabetes?

NCT ID NCT07333313

Disease control Sponsor: National Taiwan University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether taking activated bamboo charcoal and probiotics can reduce inflammation and slow kidney disease in people with diabetes. About 300 participants with different stages of chronic kidney disease will receive one or both treatments for 6 months. Researchers will track kidney function and markers of inflammation over a year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
activated bamboo charcoal and probiotics
What this could lead to
If successful, this could offer a simple, non-drug way to slow kidney damage in people with diabetes.
What could go wrong
This is an early-stage study with no phase designation, and the effects of charcoal and probiotics on kidney function are not yet proven. Results may not lead to a standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age \> 20 years old but not pregnant on the day of screening. 2. DKD patients with stable renal function (Cre elevation \< 0.3 mg/dL for at least 30 days) and PCS level (fluctuation \< 10% for at least 30 days) 3. Group 1: 120 DKD patients with 45\<eGFR\<60 ml/min/1.73m2 in stable status. Group 2: 120 DKD patients with 30\<eGFR\<45 ml/min/1.73m2 in stable status. Group 3: 60 DKD patients with 15\<eGFR\<30 ml/min/1.73m2 in stable status Group 4: 60 DKD patients with eGFR\<15 ml/min/1.73m2 in stable status Exclusion Criteria: 1. Baseline eGFR \> 90 ml/min/1.73m2 according to MDRD equation. 2. Patients in severe malnutrition status, albumin less than 2.0 g/dL. 3. Patients in severe anemia or active gastrointestinal bleeding with hemoglobulin \< 8 g/dL. 4. Active peptic ulcer, esophageal varices, ileus or under fasting status 5. Previous gastrointestinal operation. 6. Chronic constipation, as defined with less than 3 bowel movements per week, straining, hard stools. 7. Incomplete evacuation and inability to pass stool. If usage of oral laxatives can achieve bowel movement, this patient will not be excluded. 8. Patients with major hemorrhage, as defined with acute hemorrhage and requirement of blood transfusion during index admission. 9. Patients with a biopsy proved or clinically diagnosed advanced liver cirrhosis, Child classification B or C. 10. Solid organ or hematological transplantation recipients. 11. Evidence of obstructive kidney injury or polycystic kidney disease. 12. Presence or history of malignant neoplasms within the past 5 years prior to the day of screening. 13. Patients with Immune Deficiency Syndrome. 14. Antibiotics or probiotics treatment within the last 3 months before enrollment and during follow-up period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Oral uremic toxin absorbent

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Taiwan University Hospital.

    RECRUITING

    Taipei, Taiwan, 10002, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.